MedTrace Logo

Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

NCT03588806 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-06-17

Study results available
· View outcomes & findings →

Summary

This study will examine how the use of Xtampza ER, an opioid analgesic packaged in openable microsphere-containing capsules, affects swallowing satisfaction, pain, and physical and mental health outcomes in chronic pain patients.

Conditions

Interventions

DRUG

Xtampza ER (oxycodone)

Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.

Sponsors & Collaborators

  • Collegium Pharmaceutical, Inc.

    collaborator INDUSTRY

  • Ajay Wasan, MD, Msc

    lead OTHER

Principal Investigators

  • Ajay D Wasan, MD, MSc · University of Pittsburgh

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-07-31
Completion
2019-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03588806 on ClinicalTrials.gov